Hearing Aid: Decibel Therapeutics CEO Laurence Reid Talks to Close to the Edge

Taking a gene therapy approach, Decibel targets various forms of hereditary deafness (single-gene disorders) as well as other auditory and balance disorders.


In Close to the Edge, Episode 6, Decibel Therapeutics CEO Laurence Reid, PhD, talks about his career highlights and turning points leading up to his role at Decibel; the company’s strategy and prospects; its business partnerships including a manufacturing deal with Catalent; the future of genetic therapies; and the pain of England’s defeat in the final of EURO 2020 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleSelf-Injecting Pill Could Allow Oral Delivery of Monoclonal Antibody and Other Protein Drugs
Next articleConnecting the Elements of Bioprocessing Operations